👋 Hey, let’s get into it. Sam Altman is taking the conductor’s podium at Orchestra Bio. The ensemble includes clinical, manufacturing, and regulatory teams, all playing slightly different versions of the same development plan.

OpenAI acquired the company and is bringing its drug-development coordination platform into Rosalind, its life-sciences AI tools. Orchestra’s agents can trace how a failed manufacturing batch affects studies and timelines, then help people decide what to do next.

Getting an orchestra to follow one conductor sounds manageable. Getting biotech departments to agree on a timeline might require a bigger baton.

🏆 GSK Wins FDA Approval for Hepatitis B Functional Cure
Following Japan’s August approval, GSK’s Hibsago (bepirovirsen) has FDA clearance for selected adults with chronic hepatitis B. Added to existing antivirals for six months, it produced a functional cure in 19% of trial participants versus none on placebo: viral DNA and surface antigen remained undetectable six months after all treatment stopped, but Viral reservoirs can still remain. Eligibility requires no cirrhosis, at least six months of antivirals, suppressed virus, and surface antigen ≤3,000 IU/mL. For some patients, treatment measured in years could finally have an end date.

💻 NVIDIA and Nobel Winner David Baker’s Institute Release a Protein Design Model
NVIDIA and the University of Washington’s Institute for Protein Design, led by David Baker, released RFD4-Proteina, an open model for designing and refining proteins. Researchers can specify molecular targets, constraints, and scoring goals, then generate candidates to test. NVIDIA reports stronger computational results than evaluated baselines across tasks including protein binding and enzyme scaffolding. Availability through platforms including Benchling and Hugging Face could help researchers bring it into existing workflows. The computer can propose a protein, but the wet lab still gets a vote.

📉 EyePoint Plans 53% Staff Cut After Another Phase 3 Miss
EyePoint shares plunged more than 84% Monday morning after Duravyu missed the primary vision endpoint in LUCIA, its second pivotal setback in wet age-related macular degeneration. The sustained-delivery treatment failed to establish noninferiority to Eylea despite reducing injection burden. EyePoint will cut approximately 53% of its workforce and end its wet-AMD trials early, targeting roughly $30 million in annual savings. Development continues in diabetic macular edema, with Phase 3 results expected in late 2027. Fewer injections remain an attractive goal, but the vision results have to deliver too.

🤝 Astellas Signs $400M+ Deal With AI Proteins
Astellas partnered with Boston’s AI Proteins to build miniprotein medicines against multiple undisclosed targets. These small engineered proteins are designed from scratch to bind chosen targets, rather than starting with a natural protein and modifying it. AI Proteins gets an undisclosed upfront payment and could receive more than $400 million in combined upfront and milestone payments, plus royalties. Astellas receives exclusive worldwide rights and takes over subsequent development and commercialization. It’s a discovery-stage bet with plenty of experiments ahead. The proteins may be mini, but the milestone dollars certainly aren’t.

Reach 2,200+ scientists, founders, investors, operators, and other professionals across biotech and pharma.

We feature one exclusive sponsor per issue, giving relevant tools, software, services, events, and other life-science brands a direct way to reach our readers.

Think your company could be a fit? Reply to this email and let’s talk.

Alright, back to the newsletter.

✅ GSK’s Jemperli Wins FDA Approval in Rectal Cancer
The FDA granted GSK’s Jemperli accelerated approval for previously untreated, MSI-H/dMMR stage II/III rectal cancer, potentially allowing eligible patients to avoid surgery, chemotherapy, and radiation.

💉 Novo’s GLP-1 Combo Shows 25% Weight Loss in Women
Novo’s post hoc analysis estimated 25% weight loss with CagriSema versus 3% on placebo in women at 68 weeks, assuming full treatment adherence.

🙌 AstraZeneca and Amgen’s Tezspire Reaches 69% Tissue Remission
Detailed Phase 3 results showed Tezspire achieved up to 69% tissue remission versus 3.5% on placebo in eosinophilic esophagitis, with improved swallowing symptoms.

🤝 Ambrose Buys AM-Pharma for Up to $181M
Ambrose acquired AM-Pharma for up to €161 million ($181M), including milestones, adding an enzyme-replacement candidate being developed for an inherited disorder affecting bone mineralization.

🏭 Samsung Biologics’ Revenue Rises 18.5% as Capacity Ramps
Samsung Biologics’ quarterly revenue rose 18.5% as newer manufacturing capacity contributed, prompting it to raise full-year revenue growth guidance to 20% from 15–20%.

💼 CSL Names ViiV’s Deborah Waterhouse as Its Next CEO
CSL appointed longtime ViiV Healthcare chief Deborah Waterhouse as its next CEO and managing director, with her tenure beginning on February 1, 2027.

💊 Gilead’s Ulcerative Colitis Pill Delivers 31% Remission in Phase 2
Gilead’s emvistegrast met its Phase 2 goal, with 31% remission versus 8% on placebo at 12 weeks. Phase 3 is planned for 2027.

🧠 Roche Adds Brain Inflammation Data to Its MS Drug Case
New Phase 3 analyses linked Roche’s investigational fenebrutinib to up to 30% lower slowly expanding brain-lesion volume versus active comparators in multiple sclerosis.

The number behind the joke comes from a new ICER–West Health report: approximately $257,000 was the median net launch price for drugs introduced in 2025.

“Net” means after rebates and discounts, rather than what an individual patient pays at the pharmacy. The dataset also includes one-time treatments, so these aren’t all recurring annual bills. Still, that median rose 35% from 2022 after adjusting for inflation, and nearly one-quarter of 2025 launches exceeded $500,000. Free shipping probably isn’t closing the affordability gap.

There’s a wrinkle: the median actually dipped about 2% from 2024. Different medicines launched each year, so the comparison reflects a changing mix of products rather than repeated price increases on the same drugs.

Then there’s getting the prescription filled. In a separate analysis of 26 outpatient drugs, approximately one-third of new-to-brand prescriptions were filled within 30 days during the first year after approval. Coverage restrictions and blocks on newly marketed drugs were among the barriers. The report doesn’t establish that price caused every unfilled prescription.

For biotech and pharma teams, approval is a huge achievement, but access needs its own development plan. Manufacturers want returns on risky research. Payers want evidence those prices deliver enough benefit. Patients need those negotiations to end with medicine they can actually obtain.

The market-access team probably deserves a seat at the table well before launch. But whoever suggested free shipping can probably sit this meeting out.

This is the number of estimated measles cases worldwide among children under five in 2023, up 40% from 2019. A newly published Nature Medicine analysis highlights how fragile vaccination gains remain, with global first-dose coverage slipping from 83.6% to 81% over that period.

Here’s what biotech Redditors are talking about:

🎬 Biotech Redditors Review the Elizabeth Holmes Movie
Biotech Redditors have thoughts on You Can See Everything, the new Elizabeth Holmes documentary. Some debated whether it makes her too sympathetic, while others dissected the science. One viewer recalled her partner Billy Evans watching biology 101 lectures at 2x speed, which went over about as well as you’d expect. It’s not every day a biotech founder gets this much pop culture attention. Sure, the circumstances aren’t ideal, but at this point, we’ll take what we can get.

🇺🇸 Why Does Pharma Keep Choosing America?
The short answer can be broken down into three words: money, cash, dollars. A Redditor linked a report about British-Swedish pharma giant AstraZeneca’s U.S. focus and asked why pharma keeps choosing America. Commenters pointed to higher drug revenues, talent, capital, and research infrastructure. Some argued those revenues fund risky science; while others said they also enable waste, with one describing a departmental year-end spending spree. Somewhere, a perfectly functional centrifuge is about to be replaced in the name of innovation, and a Thermo Fisher sales rep just hit their year-end target. Another magical day in biotech.

🏛️ CBER’s Director Says Stability and Staffing Come First
CBER Director Karim Mikhail said rebuilding staffing and morale remains a priority alongside rare disease regulatory work, describing signs of greater stability at the center.

📱 FDA Clarifies Labeling for Prescription Drug Apps
The FDA finalized guidance explaining when companion-app content belongs in prescription drug labeling, when it counts as promotional material, and what manufacturers should submit.

🗺️ Human Embryo Atlas Connects Gene Activity With Metabolism
Researchers mapped gene activity and metabolites across one human embryo during early organ formation, creating a spatial resource for studying how tissues develop.

🤖 AstraZeneca and Oracle Explore AI Trial Recruitment
AstraZeneca and Oracle signed a nonbinding agreement to explore using AI and real-world data to help care teams identify patients eligible for clinical trials.

🛡️ Nouscom Raises $135M to Intercept Cancer Before It Develops
Nouscom raised a €120 million ($135 million) Series D, co-led by M Ventures and Revelation Partners, to advance NOUS-209 into a global registration enabling trial. The off-the-shelf immunotherapy is designed for people with Lynch syndrome, an inherited DNA repair condition that raises cancer risk. Viral vectors deliver 209 shared cancer-associated markers, aiming to train immune cells to recognize emerging trouble before invasive tumors develop. Longer term early study data are due at ESMO on October 25. The ambition is to move oncology’s starting line.

🧬 October 22, 1903: The Scientist Who Connected Genes to Chemistry Is Born
George Beadle was born in Wahoo, Nebraska, on this day in 1903. Working with Edward Tatum, he studied bread mold whose mutations prevented it from making particular nutrients. Supply the missing nutrient, and growth returned, connecting inherited changes to specific biochemical steps. Their work helped establish the historic “one gene, one enzyme” hypothesis and earned them shares of the 1958 Nobel Prize in Physiology or Medicine. Most people see a little mold and toss the entire loaf. These two helped build biochemical genetics and won a Nobel Prize…Talk about overachievers.

Halloween is coming up, and if you need a last-minute couples costume, I’ve got you: Nathan Fielder and Elizabeth Holmes.

Better yet, why limit this to Halloween? Wear it to your next pharma conference. The networking should take care of itself.

Seriously, if anyone does this for Halloween or a conference 🙏, send us photographic evidence. With your permission, we’d love to share it in the newsletter.

That’s all for today. See you Tuesday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead